PURAPHARM CORPORATION LIMITEDPURAPHARM CORPORATION LIMITEDPURAPHARM CORPORATION LIMITED

PURAPHARM CORPORATION LIMITED

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪229.06 M‬HKD
−0.22HKD
‪−106.08 M‬HKD
‪406.86 M‬HKD
‪176.44 M‬
Beta (1Y)
0.26
Employees (FY)
662
Change (1Y)
−1 −0.15%
Revenue / Employee (1Y)
‪614.59 K‬HKD
Net income / Employee (1Y)
‪−160.24 K‬HKD

About PURAPHARM CORPORATION LIMITED


CEO
Yu Ling Chan
Headquarters
Hong Kong
Founded
1998
FIGI
BBG009H9X7M6
PuraPharm Corp. Ltd. is an investment holding company, which engages in the research and development, production and sale of concentrated Chinese medicine granule (CCMG) products and Chinese healthcare products, as well as rendering of Chinese medical diagnostic services. It operates through the following segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics and Plantation. The China CCMG segment manufactures, sells, and researches modernized Chinese medicines in Mainland China. The Hong Kong CCMG segment handles sale of CCMG products excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment consists of operations in Hong Kong, the USA and Japan. The Clinics segment provides Chinese medical diagnostic services. The Plantation segment focuses on the plantation and trading of raw Chinese herbs, and manufacture and sale of TCM decoction pieces. The company was founded by Yu Ling Chan on May 5, 1998 and is headquartered in Hong Kong.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 1498 is 0.60 HKD — it has increased by 3.45% in the past 24 hours. Watch PURAPHARM CORPORATION LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange PURAPHARM CORPORATION LIMITED stocks are traded under the ticker 1498.
1498 stock hasn't changed in a week, the month change is a −9.09% fall, over the last year PURAPHARM CORPORATION LIMITED has showed a −33.33% decrease.
1498 reached its all-time high on Jul 14, 2015 with the price of 5.57 HKD, and its all-time low was 0.56 HKD and was reached on Jun 1, 2020. View more price dynamics on 1498 chart.
See other stocks reaching their highest and lowest prices.
1498 stock is 29.41% volatile and has beta coefficient of 0.26. Track PURAPHARM CORPORATION LIMITED stock price on the chart and check out the list of the most volatile stocks — is PURAPHARM CORPORATION LIMITED there?
Today PURAPHARM CORPORATION LIMITED has the market capitalization of ‪237.03 M‬, it has decreased by −1.67% over the last week.
Yes, you can track PURAPHARM CORPORATION LIMITED financials in yearly and quarterly reports right on TradingView.
PURAPHARM CORPORATION LIMITED is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
1498 net income for the last half-year is ‪−18.69 M‬ HKD, while the previous report showed ‪−68.41 M‬ HKD of net income which accounts for 72.68% change. Track more PURAPHARM CORPORATION LIMITED financial stats to get the full picture.
No, 1498 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 662.00 employees. See our rating of the largest employees — is PURAPHARM CORPORATION LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PURAPHARM CORPORATION LIMITED EBITDA is ‪14.84 M‬ HKD, and current EBITDA margin is −0.74%. See more stats in PURAPHARM CORPORATION LIMITED financial statements.
Like other stocks, 1498 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PURAPHARM CORPORATION LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PURAPHARM CORPORATION LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PURAPHARM CORPORATION LIMITED stock shows the sell signal. See more of PURAPHARM CORPORATION LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.